103
Table 25. Recommended Monitoring for Patients Taking Other
Antiarrhythmic Drugs
Drug Baseline Testing Follow-Up Testing
Additional Follow-
Up Testing
Procainamide 12-lead ECG*
Blood pressure
ECG monitoring
for assessment of
rhythm, QRS width
and QTc interval
is recommended
during the infusion
to minimize the risk
of procainamide-
associated ventricular
proarrhythmia,
including TdP
Blood pressure
monitoring is
recommended during
the infusion to detect
clinically relevant
hypotension
—
Sotalol 12-lead ECG*
Continuous ECG
monitoring during
3-d hospitalization
for sotalol initiation
Serum potassium
and magnesium
concentration
Serum creatinine for
estimation of CrCl
In 3-6 mo:
12-lead ECG*
Serum potassium
and magnesium
concentration
Serum creatinine for
estimation of CrCl
Every 3–6 mo
(more frequently
for patients
concomitantly
taking other QT
interval-prolonging
drugs or with
changing kidney
function):
12-lead ECG*
Serum potassium
and magnesium
concentration
Serum creatinine for
estimation of CrCl
* Assess rhythm and calculate QTc.
†
To facilitate early detection of potential dronedarone-associated hepatotoxicity.
(cont'd)
